Express News | HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $36 Price Target
Benzinga15:46 ET
Optimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy Data
TipRanksMay 3 06:26 ET
Express News | Dyne Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities Are Anticipated to Fund Operations Through 2025
ReutersMay 2 16:48 ET
Express News | Dyne Therapeutics Q1 EPS USD -0.81 Vs. Ibes Estimate USD -0.8
ReutersMay 2 16:10 ET
Express News | Dyne Therapeutics Q1 Operating Income USD -69.157 Million Vs. Ibes Estimate USD -66.4 Million
ReutersMay 2 16:10 ET
Express News | Dyne Therapeutics Q1 Basic EPS USD -0.81
ReutersMay 2 16:10 ET
Express News | Dyne Therapeutics Q1 Net Income USD -65.649 Million Vs. Ibes Estimate USD -64.9 Million
ReutersMay 2 16:10 ET
Express News | Dyne Therapeutics Q1 Operating Expenses USD 69.157 Million
ReutersMay 2 16:10 ET
Express News | Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
ReutersMay 2 16:10 ET
Dyne Therapeutics 1Q Loss $65.6M >DYN
Dyne Therapeutics 1Q Loss $65.6M >DYN
Dow JonesMay 2 16:10 ET
Express News | Morgan Stanley Initiates Coverage On Dyne Therapeutics With Overweight Rating, Announces Price Target of $40
BenzingaApr 30 05:17 ET
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)
TipRanksApr 30 05:01 ET
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Seeking AlphaApr 23 10:29 ET
Form 144 | Dyne Therapeutics(DYN.US) Officer Proposes to Sell 5.23 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 4, $Dyne Therapeutics(DYN.US)$ Officer Brumm Joshua T intends to sell 182.02K shares of its common stock on Apr 4, with a total market value of approximately $5.23 million.
moomoo NewsApr 4 16:28 ET
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with
GlobeNewswireMar 27 16:05 ET
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with
GlobeNewswireMar 27 08:30 ET
Dyne Therapeutics Price Target Maintained With a $47.00/Share by Oppenheimer
Dyne Therapeutics Price Target Maintained With a $47.00/Share by Oppenheimer
Dow JonesMar 26 10:18 ET
Express News | Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $47 Price Target
Moomoo 24/7Mar 26 10:07 ET
Analysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)
TipRanksMar 26 08:00 ET
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell
Dyne Therapeutics (DYN) said Monday its President and Chief Executive Joshua Brumm has stepped down to pursue a career in healthcare investing, effective immediately. The clinical-stage muscle disease
MT NewswiresMar 25 09:20 ET
No Data
No Data